Feature|Articles|February 15, 2024
- Pharmaceutical Executive: February 2024
- Volume 44
- Issue 1
Pharmaceutical Executive: February 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive February 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Central to the Missionalmost 2 years ago
Two Frameworks for Orphan Drug IDN Launch Planningalmost 2 years ago
Sustainability and Progress Continue to Make Headlines in 2024almost 2 years ago
Building Resiliency: Essential Leadership Principles for 2024almost 2 years ago
Will Strong Early-Year Vibes Translate to More Stabilization Ahead?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
2
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
3
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5